USP and Phlow Partner to Validate Continuous Manufacturing Processes

The United States Pharmacopeia (USP) and Phlow have teamed up to develop a new lab that will certify and validate pharmaceutical continuous manufacturing processes to facilitate the supply of U.S.-manufactured essential medicines.

Richmond, Va.-based Phlow manufactures active pharmaceutical ingredients (API) and finished pharmaceutical products using continuous flow technology.

The alliance will facilitate Phlow’s application of ‘flow’ chemistry and other continuous advanced manufacturing processes to produce ingredients that enable domestic manufacturing of essential medicines that “have been or are at risk of being in shortage thereby contributing to a more resilient medicines supply chain,” the partners said.

Under the agreement, the methods resulting from the partnership will be shared with other domestic generics manufacturers.

About Phlow Corporation

Phlow Corporation  is a public benefit pharmaceutical manufacturing company on a mission to reliably supply affordable, high-quality, essential medicines through U.S.-based advanced manufacturing processes. Phlow manufactures precursor chemical ingredients, Active Pharmaceutical Ingredients (API), and finished pharmaceutical products, domestically for essential medicines critical to the Nation’s healthcare. To help ensure the quality, safety, and affordability of pharmaceutical products of strategic importance to the United States, Phlow utilizes advanced manufacturing platforms, including continuous manufacturing, to provide essential medicines to its customers, health systems and government partners.

December 15, 2022

https://www.fdanews.com/

https://www.linkedin.com/